Literature DB >> 28692945

Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity.

Richard Brown1, Moira R Riley2, Lydia Ulrich3, Ellen Percy Kraly4, Paul Jenkins5, Nicole L Krupa6, Anne Gadomski7.   

Abstract

BACKGROUND: Prescription Drug Monitoring programs (PDMPs) are intended to reduce opioid prescribing and aberrant drug-related behavior thereby reducing morbidity and mortality due to prescription opioid overdose. Expansion of the New York (NY) State's PDMP in 2013 included the institution of the I-STOP law that mandated clinicians to consult the statewide PDMP database to review the patient's prescription history prior to prescribing opioids.
METHODS: Trends in prescription opioid distribution, prescribing, and prescription opioid and heroin overdose morbidity in NY were analyzed using time series. A Chow test was used to test the difference in trends before and after the implementation of I-STOP.
RESULTS: The results indicated that: 1) the number of opioid prescriptions appears to be declining following the implementation of the I-STOP, 2) however, supply chain data shows that the total quantity of opioids in the supply chain increased, 3) statewide trends in inpatient and emergency department visits for prescription opioid overdose increased from 2010 to the third quarter of 2013 where the slope leveled off following I-STOP, but this change in slope was not significant, 4) visits for heroin overdose started escalating in 2010 and continued to increase through the second quarter of 2016. The overall significance of these findings show a small impact of PDMPs on prescription opioid overdose morbidity in NY in the context of the increasing national trend during this time period.
CONCLUSIONS: Prescription opioid morbidity leveled off following the implementation of a mandated PDMP although morbidity attributable to heroin overdose continued to rise.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heroin; I-STOP; Overdose morbidity; Prescription drug monitoring program; Prescription opioids

Mesh:

Substances:

Year:  2017        PMID: 28692945     DOI: 10.1016/j.drugalcdep.2017.05.023

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  19 in total

1.  Prescription Drug Monitoring Program Use: National Dental PBRN Results.

Authors:  J L McCauley; G H Gilbert; D L Cochran; V V Gordan; R S Leite; R B Fillingim; K T Brady
Journal:  JDR Clin Trans Res       Date:  2018-10-29

2.  Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US-Mexico Border.

Authors:  David Goodman-Meza; Maria Elena Medina-Mora; Carlos Magis-Rodríguez; Raphael J Landovitz; Steve Shoptaw; Dan Werb
Journal:  Am J Public Health       Date:  2018-11-29       Impact factor: 9.308

3.  Prescription Drug Monitoring Programs and Prescription Opioid-Related Outcomes in the United States.

Authors:  Victor Puac-Polanco; Stanford Chihuri; David S Fink; Magdalena Cerdá; Katherine M Keyes; Guohua Li
Journal:  Epidemiol Rev       Date:  2020-01-31       Impact factor: 6.222

4.  Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses: A Systematic Review.

Authors:  David S Fink; Julia P Schleimer; Aaron Sarvet; Kiran K Grover; Chris Delcher; Alvaro Castillo-Carniglia; June H Kim; Ariadne E Rivera-Aguirre; Stephen G Henry; Silvia S Martins; Magdalena Cerdá
Journal:  Ann Intern Med       Date:  2018-05-08       Impact factor: 25.391

Review 5.  The Association of State Opioid Misuse Prevention Policies With Patient- and Provider-Related Outcomes: A Scoping Review.

Authors:  Amanda I Mauri; Tarlise N Townsend; Rebecca L Haffajee
Journal:  Milbank Q       Date:  2019-12-04       Impact factor: 4.911

6.  Opioid-prescribing Patterns for Pediatric Patients in the United States.

Authors:  Cornelius B Groenewald
Journal:  Clin J Pain       Date:  2019-06       Impact factor: 3.442

7.  A Rapid Review of the Impact of Systems-Level Policies and Interventions on Population-Level Outcomes Related to the Opioid Epidemic, United States and Canada, 2014-2018.

Authors:  Bahareh Ansari; Katherine M Tote; Eli S Rosenberg; Erika G Martin
Journal:  Public Health Rep       Date:  2020 Jul/Aug       Impact factor: 2.792

8.  Mandatory review of a prescription drug monitoring program and impact on opioid and benzodiazepine dispensing.

Authors:  Erin L Winstanley; Yifan Zhang; Rebecca Mashni; Sydney Schnee; Jonathan Penm; Jill Boone; Cameron McNamee; Neil J MacKinnon
Journal:  Drug Alcohol Depend       Date:  2018-05-01       Impact factor: 4.492

9.  The association between pain clinic laws and prescription opioid exposures: New evidence from multi-state comparisons.

Authors:  Di Liang; Yuyan Shi
Journal:  Drug Alcohol Depend       Date:  2019-11-21       Impact factor: 4.492

10.  Effect of Automated Prescription Drug Monitoring Program Queries on Emergency Department Opioid Prescribing.

Authors:  Benjamin C Sun; Christina J Charlesworth; Nicoleta Lupulescu-Mann; Jenny I Young; Hyunjee Kim; Daniel M Hartung; Richard A Deyo; K John McConnell
Journal:  Ann Emerg Med       Date:  2017-12-13       Impact factor: 5.721

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.